Impact of histology classification on pathologic treatment response and overall survival in distal esophageal cancer patients: a propensity matched analysisSabrina Saeed, José M. Pimiento, Samer A. Naffouje et al.|Diseases of the Esophagus|2020Cited by 5
NBTXR3 Radiation Enhancing Hafnium Oxide Nanoparticles Activated By Radiotherapy In Combination With Anti-PD-1 Therapy: A Phase I StudyColette J. Shen, Tanguy Y. Seiwert, Jason Akulian et al.|International Journal of Radiation Oncology*Biology*Physics|2020Cited by 4
NBTXR3 Activated by Radiotherapy in Combination With Nivolumab or Pembrolizumab in Patients With Advanced Cancers: A Phase I TrialColette J. Shen, Tanguy Y. Seiwert, Jessica M. Frakes et al.|International Journal of Radiation Oncology*Biology*Physics|2021Cited by 1
Phase I Dose Escalation/Dose Expansion Trial of NBTXR3/SBRT in Combination with Nivolumab or Pembrolizumab for the Treatment of Anti-PD-1 Naïve or Resistant Patients with Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaC. Shen, Ammar Sukari, William Stokes et al.|International Journal of Radiation Oncology*Biology*Physics|2025Cited by 1
Contributors 4th editionAllan Caggiano, Pooja Karukonda, A.O. Naghavi et al.|Elsevier eBooks|2024Cited by 0